XXII 22nd Century Group Inc.

22nd Century Group (Nasdaq: XXII) GVB Biopharma to Exhibit at MJBizCon in Las Vegas

22nd Century Group (Nasdaq: XXII) GVB Biopharma to Exhibit at MJBizCon in Las Vegas

BUFFALO, N.Y., Nov. 15, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: ), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced that the Company’s GVB Biopharma business will attend and be an exhibitor at MJBizCon in Las Vegas on November 16 to 18, 2022.

“We’re excited to be exhibiting at MJBizCon for the fourth year, and this time with the combined GVB and 22nd Century team, including Hugh Kinsman, Steven Przybyla, Calvin Treat, John Miller, and the GVB executive team,” said James A. Mish, chief executive officer of 22nd Century Group. “MJBizCon is an excellent opportunity to showcase our technical expertise and capabilities, from receptor science and transformative plant genetics to finished ingredients and CDMO-formulated products for the global consumer products and pharmaceutical industry.”

Find GVB Biopharma at MJBizCon, November 16 to 18, 2022, at booth #9945.

About GVB Biopharma

, a 22nd Century company, is a global-scale specialty ingredient supplier and contract development & manufacturing organization (CDMO) with manufacturing locations in Nevada and Oregon. GVB is the largest merchant provider of cannabinoid extracts and isolates in North America with a focus on cannabidiol (CBD) and cannabigerol (CBG) extracted and refined at an industrial scale into distillates and isolates. GVB Biopharma’s facilities are NSF International audited and are cGMP Registered for dietary supplements manufacturing. GVB is widely regarded as a best-in-class operator with a leading position in the hemp-derived active ingredients market, with around 15% market share and growing. GVB is also a white-label contract manufacturer of tinctures, gel capsules, gummies, mints, tablets, topical, and vape offerings.

About 22nd Century Group, Inc.

22nd Century Group, Inc. (Nasdaq: ) is a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. With dozens of patents allowing it to control nicotine biosynthesis in the tobacco plant, the Company has developed proprietary reduced nicotine content (RNC) tobacco plants and cigarettes, which have become the cornerstone of the  to address the widespread death and disease caused by smoking. The Company received the first and only FDA MRTP authorization of a combustible cigarette in December 2021. In tobacco, hemp/cannabis, and hop plants, 22nd Century uses modern plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new, proprietary plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits.

Learn more at , on , on , and on .

Learn more about VLN® at .

Cautionary Note Regarding Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 1, 2022, and in the Company’s Quarterly Report filed on August 9, 2022. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

Investor Relations & Media Contact

Mei Kuo

22nd Century Group, Inc.

Director, Communications & Investor Relations

 

Darrow Associates Investor Relations

Matt Kreps

T: 214-597-8200

 



EN
15/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on 22nd Century Group Inc.

 PRESS RELEASE

22nd Century Secures $3.2 Million to Date in Warrant Exchange Transact...

22nd Century Secures $3.2 Million to Date in Warrant Exchange Transaction Newly Appointed CEO Leading Restructuring to Focus on Tobacco Industry Operations, Reduce Costs BUFFALO, N.Y., Dec. 04, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII) (the “Company”), a biotechnology company focused on utilizing advanced plant technologies to improve health and wellness, today announced the exercise of warrants by certain holders pursuant to its previously announced warrant inducement offering. During the inducement period, certain holders of the Company’s existing warrants acqui...

 PRESS RELEASE

22nd Century Appoints Larry Firestone as Chairman and CEO

22nd Century Appoints Larry Firestone as Chairman and CEO Turnaround Veteran to Focus on Unlocking Shareholder Value in Tobacco Assets BUFFALO, N.Y., Nov. 29, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII) (“22nd Century” or the “Company”), a biotechnology company focused on utilizing advanced plant technologies to improve health and wellness, today announced the appointment of Lawrence (Larry) Firestone as the Company's Chairman and Chief Executive Officer. Nora Sullivan, former Chair of the Board, commented, “Larry is a seasoned executive known for his 'hands-on...

 PRESS RELEASE

22nd Century Group Enters into Agreement to Sell Hemp/Cannabis Franchi...

22nd Century Group Enters into Agreement to Sell Hemp/Cannabis Franchise Sale Expected to Result in Immediate and Significant Reduction in Operating Costs and Cash Requirements BUFFALO, N.Y., Nov. 27, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: ) (the “Company” or “22nd Century”), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness, today announced it has reached an agreement to sell substantially all of its GVB Biopharma (“GVB”) hemp/cannabis operations to Specialty Acquisition Corporation, a Nevada corporation ...

 PRESS RELEASE

22nd Century Group Continues VLN® Expansion, Now Retailing in More Tha...

22nd Century Group Continues VLN® Expansion, Now Retailing in More Than 5,100 Stores Adds another 500+ stores BUFFALO, N.Y., Nov. 08, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: ), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness with reduced nicotine tobacco, hemp/cannabis and hops, today announced that it has again expanded its VLN® retail presence with more than 500 additional locations across 11 states. With these latest additions, 22nd Century Group’s FDA-authorized VLN® reduced nicotine content cigarett...

 PRESS RELEASE

22nd Century Group (XXII) Expands Reduced Nicotine Content Tobacco IP ...

22nd Century Group (XXII) Expands Reduced Nicotine Content Tobacco IP with Latest Technology License Additional Exclusive License with NCSU Further Expands Reduced Nicotine Content Plant Breeding Capabilities BUFFALO, N.Y., Nov. 07, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: ), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness with reduced nicotine tobacco, hemp/cannabis, and hops, today announced the signing of an additional reduced nicotine content technology license with North Carolina State University. The...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch